What's in Mati Therapeutics Inc.'s pipeline?

Mati Therapeutics Inc. has 4 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 4 in Phase 2, 0 in Phase 1.

Which companies overlap with Mati Therapeutics Inc.'s portfolio?

Top competitors by shared drug class: Ain Shams University, Allergan, Hawler Medical University, Merck Sharp & Dohme LLC, Santen Pharmaceutical Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mati-therapeutics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Mati Therapeutics Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mati Therapeutics Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 4 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Ophthalmology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ain Shams University · 1 shared drug class
Allergan · 1 shared drug class
Hawler Medical University · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
Santen Pharmaceutical Co., Ltd. · 1 shared drug class
Tampere University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mati Therapeutics Inc.:

Cite this brief

Drug Landscape (2026). Mati Therapeutics Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mati-therapeutics-inc. Accessed 2026-05-17.